A VIR-1388 clinical trial is underway to induce an HIV-specific immune response in humans.
Trials of HIV vaccine candidate have begun. The Phase 1 trial will evaluate a new vaccine called VIR-1388 for its safety and ability to induce an HIV-specific immune response in people.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has provided scientific and financial support throughout the life of the HIV vaccine concept and is providing financial support for this study. .
NIAID has funded research and development of CMV vaccine vectors since 2004. The trial is currently being funded by both parties. NIAID and the Bill & Melinda Gates Foundation, with support from Weir Biotechnology, based in San Francisco. The study, known as HVTN 142, is sponsored by Weir and conducted under the umbrella of the HIV Vaccine Trials Network (HVTN) funded by NIAID.
What is VIR-1388?
VIR-1388 is a vaccine designed to stimulate the immune system to produce T cells that can recognize HIV and initiate an immune response to prevent chronic infection. It uses a harmless version of cytomegalovirus (CMV) to deliver HIV vaccine components without causing disease. CMV has been prevalent for centuries, is often asymptomatic, and persists throughout life, indicating that the HIV vaccine has the ability to maintain effectiveness for a long period of time, possibly similar to that seen with other vaccines. Fighting immunity.
More information about the VIR-1388 clinical trial
HVTN 142 is a clinical trial taking place at ten sites in the United States and South Africa, involving 95 HIV-negative participants. These participants will be randomly divided into four groups: three receiving different doses of the vaccine, and one receiving a placebo. To prioritize safety, only individuals with asymptomatic CMV will be included in the study. Preliminary results are expected in late 2024, and there is an optional extension study that will monitor volunteers for three years after their first vaccination.
First Published: 25 Sep 2023, 11:17 IST
Show your support for agrijournalism.
Dear Patron, Thank you for being our reader. Readers like you are our inspiration to advance agri-journalism. We need your support to continue delivering quality agri journalism and reach farmers and people in every corner of rural India.
Every contribution is valuable for our future.